Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||CLL/SLL||not applicable||ME-401||Phase I||Actionable||In a Phase I trial, ME-401 treatment was well-tolerated, resulted in an objective response rate of 89% (9/10) in patients with relapsed or refractory CLL/SLL (J Clin Oncol 38: 2020 (suppl; abstr 8016); NCT02914938).||detail...|
|PubMed Id||Reference Title||Details|
|Tolerability and durable respones of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies.||Full reference...|